Loading...
A meta-analysis of efficacy and safety of sorafenib versus other targeted agents for metastatic renal cell carcinoma
BACKGROUND: Molecular targeted therapies were found to be efficacious and safer in the treatment of metastatic renal cell carcinoma (mRCC). Sorafenib is the first target agent (TA) to report a benefit in this disease and has largely established a prominent role in progression-free survival (PFS). Ho...
Na minha lista:
| Udgivet i: | Medicine (Baltimore) |
|---|---|
| Main Authors: | , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
Wolters Kluwer Health
2019
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6344165/ https://ncbi.nlm.nih.gov/pubmed/30608388 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/MD.0000000000013779 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|